Analysts Set Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Price Target at $123.33

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) has received a consensus rating of "Hold" from the twenty analysts that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and seven have given a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $123.33.

Several research firms have recently weighed in on ZBH. Wells Fargo & Company raised their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 31st. Raymond James decreased their target price on shares of Zimmer Biomet from $128.00 to $123.00 and set an "outperform" rating on the stock in a research note on Monday, October 14th. Truist Financial increased their price target on Zimmer Biomet from $117.00 to $118.00 and gave the company a "hold" rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. raised Zimmer Biomet from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Zimmer Biomet in a report on Thursday, October 31st.

Zimmer Biomet Price Performance

ZBH stock traded up $0.01 during mid-day trading on Friday, reaching $104.47. 1,253,219 shares of the company's stock were exchanged, compared to its average volume of 1,043,560. The company has a market cap of $20.80 billion, a price-to-earnings ratio of 19.86, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02. The stock's 50 day moving average is $108.37 and its 200 day moving average is $108.18. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. Zimmer Biomet has a 12-month low of $101.47 and a 12-month high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting the consensus estimate of $1.74. The company had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. Zimmer Biomet's quarterly revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the business earned $1.65 EPS. On average, research analysts expect that Zimmer Biomet will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Monday, December 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. Zimmer Biomet's dividend payout ratio is presently 18.25%.

Institutional Investors Weigh In On Zimmer Biomet

A number of large investors have recently modified their holdings of the company. Dunhill Financial LLC boosted its position in shares of Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock valued at $26,000 after purchasing an additional 218 shares during the period. Ashton Thomas Securities LLC purchased a new position in shares of Zimmer Biomet during the third quarter worth approximately $28,000. Bangor Savings Bank acquired a new position in shares of Zimmer Biomet in the 3rd quarter valued at $31,000. Brooklyn Investment Group acquired a new position in shares of Zimmer Biomet in the 3rd quarter valued at $35,000. Finally, Quarry LP purchased a new stake in Zimmer Biomet in the 2nd quarter valued at $53,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.